Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Mar-Apr;30(2):e70037.
doi: 10.1111/hel.70037.

Comparison of Cefuroxime-Based Dual Therapy With Quadruple Therapy in Helicobacter pylori-Infected Treatment-Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial

Ji-Yan Li  1 , Ji-Chun Song  2 , Xia Tian  3 , Yun-Hua Liu  4 , Xiang-Wu Ding  5 , Ya Lin  6 , Zhen-Yu Zhang  7 , Hai Zhang  8 , De-Min Li  1 , Xiao-Wei Huang  1 , Yun-Lian Hu  9 , Li Li  4 , Hong-Tian Li  2 , Chao-Qun Huang  9   10 , Pei-Yuan Li  1   6
Affiliations
Randomized Controlled Trial

Comparison of Cefuroxime-Based Dual Therapy With Quadruple Therapy in Helicobacter pylori-Infected Treatment-Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial

Ji-Yan Li et al. Helicobacter. 2025 Mar-Apr.

Abstract

Background: High-Dose Dual Therapy With Amoxicillin Has Shown Advantages to Eradicate Helicobacter pylori (H. pylori), but Not for Penicillin-Allergic Patients. It Is Recommended That Cefuroxime Could Be an Alternative, but Whether Cefuroxime Could Be Used in Dual Therapy Has Not Been Reported. This Study Aimed to Compare the Efficacy, Safety, and Compliance of Cefuroxime-Based Dual Therapy (CDT) With Cefuroxime-Based Bismuth Quadruple Therapy (CQT) to Treat H. pylori Infection.

Materials and methods: The Prospective, Multicenter, Open-Label, Randomized Controlled Trial Was Conducted to Enroll Patients With Treatment-Naive H. pylori Infection From 9 Institutions. Patients Were Randomly Assigned to CDT Group (Cefuroxime 500 Mg Three Times/Day and Vonoprazan 20 Mg Twice/Day) or CQT Group (Cefuroxime 500 Mg Twice/Day, Levofloxacin 500 Mg Once/Day, Vonoprazan 20 Mg Twice/Day, and Bismuth 220 Mg Twice/Day), both for 14 Days.

Results: 700 Patients (350 per Group) Were Enrolled. In the Intention-To-Treat Analysis, Eradication Rates Were 76.0% and 86.3% in CDT Group and CQT Group (P = 0.001). In the Modified Intention-To-Treat Analysis, Eradication Rates Were 78.9% and 89.1% (P < 0.001). In the Per-Protocol Analysis, Eradication Rates Were 80.2% and 91.2% (P < 0.001). The Incidence of Adverse Events Was Significantly Lower in CDT Group Than CQT Group (14.4% vs. 29.8%, P < 0.001). Non-inferiority Was Confirmed Between CDT and CQT Group (All P > 0.025). Compliance Was Good in Both Groups (96.0% vs. 92.8%, P = 0.073). Poor Adherence Was a Risk Factor for Reducing the Efficacy in Both Groups.

Conclusions: CQT Was More Effective Than CDT for H. pylori Eradication, Which Might Be Recommended for Penicillin-Allergic Patients. If There Were Contraindications or Intolerance of CQT, CDT Would Be an Alternative.

Trail registration: ChiCTR2300071210.

Keywords: Helicobacter pylori; bismuth quadruple therapy; cefuroxime; dual therapy.

PubMed Disclaimer

References

    1. Y. Li, H. Choi, K. Leung, F. Jiang, D. Y. Graham, and W. K. Leung, “Global Prevalence of Helicobacter pylori Infection Between 1980 and 2022: A Systematic Review and Meta‐Analysis,” Lancet Gastroenterology & Hepatology 8, no. 6 (2023): 553–564.
    1. P. Malfertheiner, F. Megraud, T. Rokkas, et al., “Management of Helicobacter pylori Infection: The Maastricht VI/Florence Consensus Report,” Gut 71, no. 9 (2022): 1724–1762, https://doi.org/10.1136/gutjnl‐2022‐327745.
    1. Helicobacter pylori Study Group, Chinese Society of Gastroenterology, and Chinese Medical Association, “Sixth Chinese National consensus Report on the Management of Helicobacter Pylori Infection (Treatment Excluded),” Chinese Journal of Digestive Diseases 42, no. 5 (2022): 289–303.
    1. M. Kato, H. Ota, M. Okuda, et al., “Guidelines for the Management of Helicobacter pylori Infection in Japan: 2016 Revised Edition,” Helicobacter 24, no. 4 (2019): e12597.
    1. Y. T. Kuo, J. M. Liou, E. M. El‐Omar, et al., “Primary Antibiotic Resistance in Helicobacter pylori in the Asia‐Pacific Region: A Systematic Review and Meta‐Analysis,” Lancet Gastroenterology & Hepatology 2, no. 10 (2017): 707–715.

Publication types

MeSH terms

LinkOut - more resources